Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 4Leukemia, Lymphocytic, Chronic, B-Cell 3Neoplasms 2Hematologic Neoplasms 2Rare Diseases 1Neurologic Manifestations 1Neuroblastoma 1Neoplasms, Plasma Cell 1Myasthenia Gravis 1Mental Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphoma 1Leukemia 1Infections 1Burkitt Lymphoma 1Agammaglobulinemia 1

Interventions

Bevacizumab 4Temozolomide 3Irinotecan 3Sorafenib 2Radiosurgery 2pembrolizumab 1ibrutinib 1Vorinostat 1Valproic Acid 1Transcranial Magnetic Stimulation 1Therapeutics 1Thalidomide 1Standard of Care 1Sildenafil Citrate 1Radiotherapy 1Pliability 1Plasma Exchange 1Palliative Care 1Nivolumab 1Morphine 1Methadone 1Lenalidomide 1Immunoglobulins 1Exercise 1Equipment and Supplies 1Clomipramine 1Carboplatin 1Bendamustine Hydrochloride 1Atorvastatin 1Amifampridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neurologic Manifestations × Immunoglobulins × Clear all
NCT00004682 2015-03-25

Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis

FDA Office of Orphan Products Development

Phase NA Terminated
100 enrolled

Mental Disorders, Myasthenia Gravis, Neurologic Manifestations, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡